DGIdb - CHLORAMBUCIL Drug Record

CHLORAMBUCIL chembl:CHEMBL515 ApprovedAntineoplasticImmunotherapy

Alternate Names:

CHLORAMBUCIL
NSC-3088
LEUKERAN
CB-1348
NCI-3088
CHLORBUTIN
4-(P-BIS(Β-CHLOROETHYL)AMINOPHENYL)BUTYRIC ACID
GAMMA-[P-DI(2-CHLOROETHYL)AMINOPHENYL]BUTYRIC ACID
4-(P-BIS(BETA-CHLOROETHYL)AMINOPHENYL)BUTYRIC ACID
CHLORAMINOPHEN
N,N-DI-2-CHLOROETHYL-Γ-P-AMINOPHENYLBUTYRIC ACID
Γ-[P-DI(2-CHLOROETHYL)AMINOPHENYL]BUTYRIC ACID
LEUKERAN®
N,N-DI-2-CHLOROETHYL-GAMMA-P-AMINOPHENYLBUTYRIC ACID
AMBOCHLORIN
PHENYLBUTYRIC ACID NITROGEN MUSTARD
4-[P-[BIS(2-CHLOROETHYL)AMINO]PHENYL]BUTYRIC ACID
drugbank:00291
chembl:CHEMBL515
rxcui:2346
chemidplus:305-03-3
pubchem.compound:2708

Drug Info:

(3 More Sources)

Publications:

Preuss et al., 1996, Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs., Int. J. Cancer
Butrym A et al., 2016, Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia., HLA
Ziemba et al., 2001, Repair of triplex-directed DNA alkylation by nucleotide excision repair., Nucleic Acids Res.
Depeille et al., 2004, Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects., Mol. Pharmacol.
Hunter et al., 2014, Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer., Mol. Cancer Ther.
van der Heijden et al., 2005, In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor., Clin. Cancer Res.

CHLORAMBUCIL FANCC

Interaction Score: 2.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16243825

Sources:
CIViC
CHLORAMBUCIL CXCL12

Interaction Score: 1.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27173875

Sources:
PharmGKB
CHLORAMBUCIL MGMT

Interaction Score: 0.54

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8621235

Sources:
NCI
CHLORAMBUCIL GSTM1

Interaction Score: 0.49

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15044619

Sources:
NCI
CHLORAMBUCIL BRCA2

Interaction Score: 0.41

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal adenocarcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
25193512

Sources:
JAX-CKB
CHLORAMBUCIL GFER

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHLORAMBUCIL BRCA1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
25193512

Sources:
JAX-CKB
CHLORAMBUCIL ERBB2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11691913

Sources:
NCI
CHLORAMBUCIL RORC

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHLORAMBUCIL NFKB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHLORAMBUCIL BAZ2B

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHLORAMBUCIL TP53

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

NCI: CHLORAMBUCIL

Version: 14-September-2017

Alternate Names:

C362 NCI drug code

Drug Info:

Publications:

Preuss et al., 1996, Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs., Int. J. Cancer

Ziemba et al., 2001, Repair of triplex-directed DNA alkylation by nucleotide excision repair., Nucleic Acids Res.

Depeille et al., 2004, Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects., Mol. Pharmacol.

JAX-CKB: Chlorambucil
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Hunter et al., 2014, Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer., Mol. Cancer Ther.
PharmGKB: chlorambucil
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Butrym A et al., 2016, Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia., HLA
CIViC: CHLORAMBUCIL
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

van der Heijden et al., 2005, In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor., Clin. Cancer Res.
TTD: Chlorambucil
- Version: 2020.06.01
Alternate Names:

D0V8QT TTD Drug ID

Drug Info:

Publications:
DTC: CHLORAMBUCIL
- Version: 02-September-2020
Alternate Names:

CHEMBL515 ChEMBL Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL515
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	colorectal adenocarcinoma
Response Type	sensitive
Approval Status	Preclinical

Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	sensitive
Approval Status	Preclinical

CHLORAMBUCIL Drug Record

CHLORAMBUCIL chembl:CHEMBL515 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16243825

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27173875

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8621235

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15044619

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colorectal adenocarcinoma Response Type sensitive Approval Status Preclinical

PMIDs: 25193512

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type triple-receptor negative breast cancer Response Type sensitive Approval Status Preclinical

PMIDs: 25193512

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11691913

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

NCI: CHLORAMBUCIL

Alternate Names: C362 NCI drug code

Drug Info:

JAX-CKB: Chlorambucil

Alternate Names:

Drug Info:

Publications: Hunter et al., 2014, Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer., Mol. Cancer Ther.

PharmGKB: chlorambucil

Alternate Names:

Drug Info:

Publications: Butrym A et al., 2016, Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia., HLA

CIViC: CHLORAMBUCIL

Alternate Names:

Drug Info:

Publications: van der Heijden et al., 2005, In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor., Clin. Cancer Res.

TTD: Chlorambucil

Alternate Names: D0V8QT TTD Drug ID

Drug Info:

Publications:

DTC: CHLORAMBUCIL

Alternate Names: CHEMBL515 ChEMBL Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL515

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
16243825

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
27173875

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
8621235

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15044619

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal adenocarcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
25193512

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
25193512

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
11691913

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

C362 NCI drug code

Publications:

Hunter et al., 2014, Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer., Mol. Cancer Ther.

Publications:

Butrym A et al., 2016, Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia., HLA

Publications:

van der Heijden et al., 2005, In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor., Clin. Cancer Res.

Alternate Names:

D0V8QT TTD Drug ID

Alternate Names:

CHEMBL515 ChEMBL Drug ID